In the Lux-Lung clinical trials [6], afatinib monotherapy demonstrated a progression-free survival (PFS) of 10.7 months (95% confidence interval 5.6–14.7) in patients with NSCLC harboring uncommon EGFR mutations (excluding exon 20 insertion- and T790M-positive groups) in the front-line setting. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.